Home/Pipeline/EIK-003

EIK-003

Oncology (Undisclosed)

DiscoveryActive

Key Facts

Indication

Oncology (Undisclosed)

Phase

Discovery

Status

Active

Company

Eikon Therapeutics

About Eikon Therapeutics

Eikon Therapeutics' mission is to pioneer a new paradigm in drug discovery by directly observing the dynamic behavior of proteins in living cells, a field it terms 'dynamic biology.' The company has successfully built and scaled its proprietary platform, transitioned to a public company (NASDAQ: EIKN), and advanced a pipeline of five disclosed programs. Its strategy is to leverage its unique observational biology platform to identify and prosecute novel, high-value targets with the potential for first-in-class or best-in-class therapeutics.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Oncology (Undisclosed) Drugs

Drug	Company	Phase	Status
CLD-601	Calidi Biotherapeutics	Discovery	Active
Protease Inhibitor Discovery Programs	Medivir	Discovery	Active
Nucleoside/Nucleotide Discovery Programs	Medivir	Discovery	Active
Orion Collaboration Program 1	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 2	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 3	Glykos Finland	Research/Preclinical	Active
Orion Collaboration Program 4-6 (Extended)	Glykos Finland	Research	Active
NEX-20	Nanexa	Preclinical	Active
NEX-18	Nanexa	Preclinical	Active
E7386	PRISM Biolabs	Phase 1	Active (Co-created with Eisai, clinical results published)
ISB 830	Glenmark Pharmaceuticals	Preclinical	Active
TEM-1	Tempus AI	Discovery/Preclinical	Active